What do systematic reviews say?

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor vs placebo

The review found no eligible studies for this question.

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ dual therapy: tezacaftor plus ivacaftor vs placebo or ivacaftor alone

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 506 participants
  Moderate

Summary of findings ‐ triple therapy: VX‐659‐tezacaftor‐ivacaftor/deutivacaftor vs control

The review found no eligible studies for this question.

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor/deutivacaftor vs control

The review found no eligible studies for this question.

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor vs control (ivacaftor alone or tezacaftor plus ivacaftor)

The review found no eligible studies for this question.

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ monotherapy: lumacaftor vs placebo

The review found no eligible studies for this question.

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ triple therapy: VX‐440‐tezacaftor‐ivacaftor vs placebo

The review found no eligible studies for this question.

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ triple therapy: VX‐152‐tezacaftor‐ivacaftor vs placebo

The review found no eligible studies for this question.

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Limited sternotomy vs full median sternotomy

• Limited versus full sternotomy for aortic valve replacement 2023 · Cochrane Headline outcomes only
  no estimate extracted
  10 studies · 1043 participants
  Very low

Ataluren vs placebo

• Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 232 participants
  High

Surfactant treatment guided by rapid tests for surfactant deficiency vs surfactant therapy provided to preterm infants with respiratory distress syndrome diagnosed on clinical and radiologic criteria

Surfactant treatment guided by rapid tests for surfactant deficiency showed no clear difference in bronchopulmonary dysplasia№ of participants: 562(3 RCTs) compared with surfactant therapy provided to preterm infants with respiratory… (low certainty).

• Surfactant therapy guided by tests for lung maturity in preterm infants at risk of respiratory distress syndrome 2023 · Cochrane Headline outcomes only
  RR 0.9 [0.61, 1.32]
  Studies not reported
  Low

Surfactant treatment guided by rapid tests for surfactant deficiency vs surfactant therapy provided to preterm infants with respiratory distress syndrome diagnosed on clinical and radiologic criteria

The review found no eligible studies for this question.

• Surfactant therapy guided by tests for lung maturity in preterm infants at risk of respiratory distress syndrome 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Digital technology (web‐based platform CFHealthHub) vs usual care

Digital technology (web‐based platform CFHealthHub) probably leads to lower number of pulmonary exacerbations compared with usual care (moderate certainty).

• Digital technology for monitoring adherence to inhaled therapies in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
  rate ratio 0.92
  1 study · 607 participants
  Moderate

Digital technology (TIM) vs standard treatment (TBM)

The review found no eligible studies for this question.

• Digital technology for monitoring adherence to inhaled therapies in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Levonorgestrel IUDs vs Copper IUDs

It is very uncertain whether summary of findings table ‐ Levonorgestrel IUDs changes rates of expulsion compared with copper IUDs (very low certainty).

• Progestin intrauterine devices versus copper intrauterine devices for emergency contraception 2023 · Cochrane Headline outcomes only
  RR 0.67 [0.11, 4]
  1 study · 655 participants
  Very low

Psychological interventions vs active comparators

• Psychological interventions for improving adherence to inhaled therapies in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 128 participants
  Very low

Psychological interventions vs usual care

• Psychological interventions for improving adherence to inhaled therapies in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 607 participants
  Moderate

High‐dose vs standard‐dose strategies

It is very uncertain whether high‐dose changes bronchopulmonary dysplasia/chronic lung disease (BPD) at 36 weeks'… compared with standard‐dose strategies (very low certainty).

• Caffeine dosing regimens in preterm infants with or at risk for apnea of prematurity 2023 · Cochrane Headline outcomes only
  RR 0.89 [0.61, 1.3]
  2 studies · 152 participants
  Very low

High‐dose vs standard‐dose strategies

It is very uncertain whether high‐dose changes bronchopulmonary dysplasia/chronic lung disease (BPD) at 36 weeks'… compared with standard‐dose strategies (very low certainty).

• Caffeine dosing regimens in preterm infants with or at risk for apnea of prematurity 2023 · Cochrane Headline outcomes only
  RR 0.72 [0.47, 1.11]
  3 studies · 333 participants
  Very low
• Caffeine dosing regimens in preterm infants with or at risk for apnea of prematurity 2023 · Cochrane Headline outcomes only
  RR 0.68 [0.48, 0.97]
  1 study · 238 participants
  Low
• Caffeine dosing regimens in preterm infants with or at risk for apnea of prematurity 2023 · Cochrane Headline outcomes only
  RR 0.75 [0.6, 0.94]
  5 studies · 723 participants
  Moderate

Summary of findings for nasal irrigation with topical steroids plus sinus surgery vs nasal irrigation with topical steroids alone

• Surgery for nasal polyposis in cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 28 participants
  Very low